Take our survey

We value your opinion. To improve your experience on emend.com, we are conducting research to better understand the needs of our visitors.

Please take a few moments to complete a short 5-question survey.

Please be assured that this survey is for research purposes only and that your privacy will be respected. Your responses will remain strictly confidential.

Any data collected in this survey will be handled in accordance with the privacy policy of Vovici, who is administering this survey on behalf of Merck.

Your responses to this survey will be kept strictly confidential and WILL NOT be used to contact you or sell you products or information.

This survey is sponsored by Merck.

Take now Take later No thanks
Aprepitant Prescribing Information

The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
Merck

Realize the full benefit of EMEND.

For patients at risk of CINV due to HEC or MEC, EMEND always should be taken on Days 1, 2, and 3 of chemotherapy treatment. When using EMEND for Injection, remember to prescribe the oral regimen of EMEND (Bifold Pack).

More information »

PDF Download Prescribing Information for EMEND in PDF format
[PDF: 222KB, 18 pages]

PDF Download Prescribing Information for EMEND for Injection in PDF format
[PDF: 154KB, 17 pages]

For information about Merck products or services, please call 866-448-7590. The Merck National Service Center will be pleased to assist you Monday through Friday from 8 AM to 7 PM ET.

20950402(6)-07/09-EME